Viral Gastroenteritis¶
Chapter 209 | Part 5: Infectious Diseases · Part 5 – Infectious Diseases: Viral (incl. HIV) · Chapter 209
Key Clinical Points¶
- Viral gastroenteritis causes ~0.5 million child deaths/year globally and accounts for 6–8% of pediatric hospitalizations in industrialized nations.
- Norovirus is responsible for ~50% of global gastroenteritis outbreaks and is the leading cause of medically attended gastroenteritis in US children.
- Rotavirus vaccines (RotaTeq, Rotarix) reduce severe disease by 85–98% in industrialized countries but are less effective (36–66%) in low-income settings.
- Diagnosis is typically a clinical exclusion based on the absence of stool leukocytes/blood and an incubation period of 1–3 days.
- Treatment is strictly supportive; oral rehydration is standard, while antibiotics and antimotility agents are contraindicated.
- Rotavirus causes severe dehydrating diarrhea in children <5 years; its impact has been reduced by >70% in the US since 2006.
- Norovirus shedding can persist for weeks post-recovery and for months in immunocompromised individuals.
- Intussusception risk from rotavirus vaccines is rare (<1/10,000 doses).
- Viral gastroenteritis is characterized by a low infectious dose (10–100 particles) and nonbloody diarrhea.
- Bacterial gastroenteritis typically requires higher infectious doses (>10⁵) and is more common in settings with poor hygiene.
1. DEFINITION & OVERVIEW¶
Acute infectious gastroenteritis is a global public health concern affecting all age groups.
• Impact: • Causes ~0.5 million child deaths/year globally. • Accounts for 6–8% of pediatric hospitalizations in industrialized nations. • Clinical Features: • Sudden onset of vomiting and diarrhea. • Absence of stool leukocytes or blood. • Incubation period: 1–3 days. • High-Risk Group: Elderly individuals with comorbidities are at highest risk for severe complications.
1.1 Etiologic Agents¶
Major viral agents include:
• Rotavirus (Reoviridae): Double-stranded RNA; causes severe dehydrating diarrhea in children <5 years.
• Norovirus (Caliciviridae): Positive-sense single-strand RNA; responsible for 50% of global outbreaks.
• Sapovirus (Caliciviridae): Positive-sense single-strand RNA; significant in children.
• Astrovirus (Astroviridae): Positive-sense single-strand RNA; significant in children.
• Adenovirus types 40/41 (Adenoviridae): Double-strand DNA; causes mild gastroenteritis.
2. EPIDEMIOLOGY¶
Rotavirus disease peaks in temperate climates during fall/winter but occurs year-round in tropical regions.
• Norovirus: • Leading cause of gastroenteritis outbreaks globally. • ~50% of US outbreaks attributed to Norovirus. • Transmission: Fecal-oral route, aerosolization, and contaminated fomites. • Shedding: Peaks during acute illness; may persist for weeks post-recovery (months in immunocompromised individuals).
• Rotavirus Epidemiology: • Before vaccination, US rotavirus season peaked in Northeast (March–May) and Southwest (October–December). • Post-vaccination (2006), this geotemporal pattern was eliminated. • Nearly all children are infected by age 3–5 years. • Mortality rates are highest in Sub-Saharan Africa and Southern Asia (≥100/100,000 PY).
2.1 Rotavirus Epidemiology¶
Developing countries have higher mortality rates (≥100/100,000 PY) and more severe disease.
2.2 Calicivirus Epidemiology¶
Norovirus transmission occurs via fecal-oral route, aerosolization, and contaminated fomites.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Rotavirus destroys mature enterocytes in proximal small intestine villi, causing secretory diarrhea and malabsorption. NSP4 protein acts as an enterotoxin.
Norovirus attaches to HBGA on gastroduodenal epithelium via carbohydrate ligands. Jejunal villi blunting and crypt hyperplasia occur during infection, leading to brush-border enzyme reduction and osmotic diarrhea.
3.1 Rotavirus Pathogenesis¶
• Viral structure: 11 segments of double-strand RNA in triple-layered capsid (75 nm).
• Proteins: VP6 determines group specificity; VP7/VP4 determine serotype.
• Groups: Seven human rotavirus groups exist, with group A causing most disease.
3.2 Norovirus Pathogenesis¶
• No specific antiviral therapy available.
• Disease self-limited with oral rehydration sufficient for most cases.
• IV fluids required for severe dehydration.
4. CLINICAL FEATURES¶
Acute onset (1–3 day incubation) with vomiting/diarrhea.
• Demographic Differences: • Children: More likely to vomit. • Adults: More prone to diarrhea.
• Stool Characteristics: Watery, nonbloody in almost all cases.
4.1 Rotavirus Clinical Manifestations¶
• Incubation period: 1–3 days
• Vomiting often precedes diarrhea
• Fever >39°C in 1/3 of cases
• Stools watery, rarely contain blood cells
• Resolution in 3–7 days
• Associated with intussusception risk (1/10,000 doses)
• Vaccine efficacy: 85–98% in industrialized countries, 36–66% in low-income settings
4.2 Norovirus Clinical Manifestations¶
• Self-limited illness with oral rehydration sufficient for most cases
• IV fluids required for severe dehydration
• No specific antiviral therapy available
4.3 Comparison of Viral vs Bacterial Gastroenteritis¶
Table 209-2 summarizes the differences between viral and bacterial agents.
5. DIFFERENTIAL DIAGNOSIS¶
Viral gastroenteritis is typically a diagnosis of exclusion.
• Key Differentiators: • Viral: Low infectious dose, winter seasonality (temperate), nonbloody diarrhea, prominent vomiting in children. • Bacterial: High infectious dose, summer/rainy seasonality (developing), bloody diarrhea, fever with inflammatory pathogens.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis is typically clinical exclusion based on the absence of stool leukocytes and blood.
• Confirmatory Tests: • EIA: Used for rotavirus and adenovirus. • RT-PCR: Used for norovirus and other pathogens. • EM/PAGE: Used for viral RNA detection.
6.1 Diagnostic Assays¶
• EIA (commercial), RT-PCR, EM, PAGE
• Commercial assays available for rotavirus and adenovirus; other agents limited to research/public health labs.
7. MANAGEMENT & TREATMENT¶
Treatment is strictly supportive.
- Supportive Care:
- Provide hydration and nutrition.
- Fluid Management:
- Oral Rehydration Solution (ORS) for most cases.
- IV fluids required for severe dehydration or when vomiting prevents oral intake.
- Contraindications:
- Antibiotics are contraindicated.
- Antimotility agents are contraindicated.
- Special Populations:
- Immunoglobulins/colostrum may be used for immunocompromised patients.
Table 209-5 Rotavirus Vaccines
| Vaccine | Manufacturer | Recommendation | Efficacy |
|---|---|---|---|
| RotaTeq | Merck, US | Routine immunization for US infants | 85–98% against severe disease |
| Rotarix | GlaxoSmithKline, Belgium | Routine immunization for US infants | 85–98% against severe disease |
| Rotavac | Bharat Biotech, India | India's routine program | 36–66% in low-income countries |
| Rotasiil | Serum Institute, India | India's routine program | 36–66% in low-income countries |
7.1 Treatment Guidelines¶
• Standard oral rehydration effective for most children
• IV fluids required for severe dehydration/vomiting
• Antibiotics/antimotility agents contraindicated
7.2 Prevention Strategies¶
• Food/water contamination control
• Hygiene measures to reduce person-to-person spread
• Rotavirus Vaccines: - RotaTeq (Merck, US): 85–98% efficacy against severe disease. - Rotarix (GSK, Belgium): 85–98% efficacy against severe disease. - Rotavac (Bharat Biotech, India): 36–66% in low-income countries. - Rotasiil (Serum Institute, India): 36–66% in low-income countries.
• Other Vaccines: VLP-based vaccines in development (47% efficacy for GI.1, 61.8% for bivalent G1.1/GII.4).
8. PROGNOSIS & COMPLICATIONS¶
• Mortality: - Rare mortality from severe dehydration in developed areas. - High mortality in developing world (Sub-Saharan Africa/Southern Asia ≥100/100,000 PY).
• Morbidity: - Reinfections common but less severe with age. - Intussusception risk: Rare (<1/10,000 doses) in high/middle-income countries; no risk identified in developing country postmarketing studies.
8.1 Mortality and Morbidity¶
Leading cause of diarrheal death in developing world.
8.2 Vaccine Safety¶
Benefit of vaccination outweighs risks despite moderate efficacy in low-income settings.
9. SPECIAL CONSIDERATIONS¶
• HIV-infected Children: Rotavirus is not a major opportunistic pathogen.
• Immunocompromised Patients: - May experience prolonged diarrhea. - May have prolonged viral shedding.
• Low-Income Settings: - Vaccine efficacy lower due to malnutrition/co-infections.
10. KEY PEARLS & CLINICAL TRAPS¶
• Vaccine Efficacy Gap: Rotavirus vaccines are highly effective in industrialized nations (85–98%) but significantly less so in low-income settings (36–66%).
• Norovirus Persistence: Be aware that shedding can occur pre-symptomatically and for weeks post-recovery.
• Intussusception Risk: While a known risk of rotavirus vaccine, it is extremely rare (<1/10,000 doses).
• Diagnostic Rule: Viral gastroenteritis is typically a diagnosis of exclusion based on the absence of inflammatory markers (leukocytes/blood).
Reference Tables¶
TABLE 209-1 Viral Causes of Gastroenteritis among Humans VIRUS Group A rotavirus Norovirus Sapovirus Astrovirus…¶
Harrison's 22e, p.1628
| VIRUS | FAMILY | GENOME | PRIMARY AGE GROUP AT RISK | CLINICAL SEVERITY |
DETECTION ASSAYS |
|---|---|---|---|---|---|
| Group A rotavirus | Reoviridae | Double-strand segmented RNA | Children <5 years | + + + | EIA (commercial), RT-PCR, EM, PAGE |
| Caliciviridae | Positive-sense single-strand RNA | All ages | + + | ||
| Sapovirus | Caliciviridae | Positive-sense single-strand RNA | Children <5 years | + | RT-PCR, EM |
| Astroviridae | Positive-sense single-strand RNA | Children <5 years | + | ||
| Adenovirus (mainly types 40 and 41) |
Adenoviridae | Double-strand DNA | Children <5 years | +/+ + | EIA (commercial), PCR, EM |
TABLE 209-2 Characteristics of Gastroenteritis Caused by Viral and Bacterial Agents FEATURE Setting Infectious dose…¶
Harrison's 22e, p.1629
| FEATURE | VIRAL GASTROENTERITIS | BACTERIAL GASTROENTERITIS |
|---|---|---|
| Setting | Incidence similar in developing and developed countries | More common in settings with poor hygiene and sanitation |
| Low (10–100 viral particles) for most agents | ||
| Seasonality | In temperate climates, winter seasonality for most agents; year-round occurrence in tropical areas |
More common in summer or rainy months, particularly in developing countries with a high disease burden |
| 1–3 days for most agents; can be shorter for norovirus | ||
| Reservoir | Primarily humans | Depending on bacterial species, human (e.g., Shigella, Salmonella), animal (e.g., Campylobacter, Salmonella, E. coli), and water (e.g., Vibrio) reservoirs exist |
| Common with rotavirus and norovirus; uncommon with other agents |
||
| Vomiting | Prominent and can be the only presenting feature, especially in children |
Common with bacteria producing preformed toxins; less prominent in diarrhea due to other agents |
| Common; nonbloody in almost all cases | ||
| Duration | 1–3 days for norovirus and sapovirus; 2–8 days for other viruses |
1–2 days for bacteria producing preformed toxins; 2–8 days for most other bacteria |
| This is often a diagnosis of exclusion in clinical practice. Commercial enzyme immunoassays are available for detection of rotavirus and adenovirus, but identification of other agents is limited to research and public health laboratories. |
||
| Treatment | Supportive therapy to maintain adequate hydration and nutrition should be given. Antibiotics and antimotility agents are contraindicated. |
Supportive hydration therapy is adequate for most patients. Antibiotics are recommended for patients with dysentery caused by Shigella or diarrhea caused by Vibrio cholerae and for some patients with Clostridium difficile colitis. |